NYSEConsumer DiscretionaryPersonal ServicesSnapshot 2026-07-23
Reading MED? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a turnaround situation with a focus on recovery. The current thesis state indicates mixed management execution and a need for improvement in financial results.
The market appears to have priced in a low expectations gap, suggesting that investors are not overly optimistic about MED's near-term recovery. Valuation is considered cheap compared to peers, but the fundamentals reflect ongoing losses.
Fundamentals are likely to remain under pressure in the near term, given the company's recent weak performance and ongoing losses. Management's ability to meet revenue and EPS loss guidance will be critical for future stability.
The long-term thesis hinges on management's execution of their revenue and cost management priorities, as well as the performance of sector bellwethers. Any changes in guidance or performance from key competitors could significantly impact MED's outlook.
In the next 1 to 3 years, MED's path will depend on its ability to navigate financial challenges and sector dynamics. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The primary driver is a sharp drop in MED's price, which suggests the market is repricing the reasons to own it. Recent financial performance has been weak, sitting below its industry peers, indicating ongoing challenges for the company.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: If revenue is below this level, it shows problems in getting new clients and keeping coaches.
Confirms:Q2 2026 revenue reported below $60 million.
Disproves:Q2 2026 revenue reported above $80 million.
Why it matters: Higher operating income means better cost management. This can lead to more profit.
Confirms:Q2 operating income was better than -$3.3 million.
Disproves:Q2 operating income was worse than -$3.3 million.
Why it matters: Meeting revenue guidance shows the company can stabilize growth in a tough market.
Confirms:Q2 revenue reported between $270M and $300M.
Disproves:Q2 revenue reported below $270M.
Why it matters: Positive revenue growth would signal a potential turnaround for Medifast. The sector is currently declining, so this change is crucial.
Confirms:Revenue growth turns positive year over year in the next earnings report.
Disproves:Revenue continues to decline year over year in the next earnings report.
Why it matters: Staying within the EPS guidance shows the company is keeping costs under control.
Confirms:Q2 diluted EPS reported between -$1.55 and -$2.75.
Disproves:Q2 diluted EPS reported worse than -$2.75.
Why it matters: A drop in revenue would show bigger problems in getting and keeping clients.
Confirms:Active earning coaches were below 14,000.
Disproves:Active earning coaches were above 16,000.
Why it matters: An EPS loss above this level shows worse financial health and more operational issues.
Confirms:EPS loss reported worse than $1.00.
Disproves:EPS loss reported better than $0.50.
